Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • heterozygous familial hypercholesterolaemia

    - PMLiVE

    NewAmsterdam’s CETP inhibitor obicetrapib shows promise in Alzheimer’s sub-study

    The trial was primarily designed to assess the LDL-C lowering efficacy of the candidate

    - PMLiVE

    NewAmsterdam shares positive phase 3 results for CETP inhibitor obicetrapib in HeFH

    Heterozygous familial hypercholesterolaemia affects approximately one in 250 people globally

    regeneron headquarters

    Regeneron’s Praluent receives FDA approval for paediatric patients with genetic high cholesterol

    Patients aged eight year or older with heterozygous familial hypercholesterolaemia will be eligible to receive the treatment

    - PMLiVE

    NewAmsterdam Pharma and Frazier LifeSciences announce merger agreement

    The agreement will provide the Dutch biotech with additional resources for its cholesterol-lowering drug candidate

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links